We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Major shareholder announcement - Pharma Equity Group A/S Major shareholder announcement - Pharma Equity Group A/S 23 April 2024Company Announcement no. 14 Pharma Equity Group A/S has, in...
Passing of the General Meeting of Pharma Equity Group A/S Passing of the General Meeting of Pharma Equity Group A/S 16 April 2024Company Announcement no. 13 Pharma Equity Group A/S today...
The Board of Director's decision to issue convertible loans The Board of Director's decision to issue convertible loans 10 April 2024Company Announcement no. 12 The Board of Directors...
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051. 5 April 2024...
Notice convening the annual general meeting in Pharma Equity Group A/S 25 March 2024 Announcement no. 10 Notice convening the annual general meeting in Pharma Equity Group A/S The board of...
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009 Date: 22 March 2024 Announcement of the Year No...
Completion of subscription of convertible loans Completion of subscription of convertible loans March 21, 2024Company Announcement no. 08 On 7 February 2024, the Board of...
Pharma Equity Group A/S - Annual Report 2023 Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7 Pharma Equity Group A/S - Annual report 2023 - main...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions